Phase 2b, Proof-of-Concept, Single-center, Double-Masked, Randomized Study Comparing the Safety, Tolerability, and Efficacy of Three Different Ophthalmic Eyelid Wipe Dosing Techniques Using IVW-1001 in Subjects With Dry Eye Disease
Latest Information Update: 10 Oct 2025
At a glance
- Drugs IVIEW 1001 (Primary)
- Indications Dry eyes
- Focus Proof of concept; Therapeutic Use
- Sponsors iView Therapeutics
Most Recent Events
- 23 Sep 2025 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Sep 2025 New trial record
- 18 Aug 2025 According to an IVIEW Therapeutics media release, the first patient has been dosed in this trial .